Abstract 19127: First Simultaneous Assessment of the Effects of Fish Oil Supplementation on Lipid and Thrombogenicity Profiles

Background: Fish Oil supplementation may have anti-atherosclerotic effects by reducing triglycerides, improving endothelial function, and reducing inflammation. However, inconsistent results have been reported on the effects of fish oil on platelet function. We aimed to determine if fish oil supplementation reduced the atherothrombotic risk profile by measuring lipids and thrombogenic factors simultaneously . Methods: Patients with suspected coronary artery disease with (n=79) and without (n=324) fish oil supplementation were enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atheroclerosis (MAGMA) study. The lipid profile was determined by vertical density gradient ultracentrifugation technique, and thrombogenicity by thrombelastography immediately prior to elective coronary angiography. Urinary 11-dehydrothromboxane B 2 and AtherOx were performed by immunoassay. ADP and collagen-induced platelet aggregation were measured in aspirin+ clopidogrel- treated patients. Results: Baseline demographics and cardiac risk factors were similar between groups. Fish oil supplementation was associated with significantly lower triglycerides, VLDL, remnant lipoproteins, and AtherOx levels and increased HDL levels (p<0.05). Among patients on aspirin + clopidogrel therapy, fish oil supplementation was associated with lower collagen-induced platelet aggregation (p=0.05, Table). Conclusion: This is the first study to simultaneously examine the influence of fish oil supplementation on lipid and thrombogenicity profiles. Our study supports prior evidence of an improved lipid profile and suggests an enhancement of the anti-platelet effects of DAPT. Prospective studies are needed to determine the contribution of each of these effects of fish oil supplementation on thrombotic event occurrence.